Just read your post – I thought you might be interested in a related follow up:

At the upcoming AACR meeting, Christian Itin, CEO of Micromet, will present on a t-cell engaging immunotherapy (known as BiTE) that actually takes the widely used colorectal cancer drug Erbitux and improves upon it by turning it into a BiTE antibody capable of going after T cells. Right now, the 40% of colorectal cancer patients who express the KRAS gene mutation do not respond to treatment with Eributx. The “Erbitux BiTE” shows activity against colon cancer regardless of whether the KRAS mutation is present.

Pretty cool science with some promosing results.

Best,
Dane

p. 415.817.2592